Gene Therapy Produces Long-term Contraception in Female Domestic Cats
The study’s findings offer a potential alternative to surgical spaying
Press ReleaseJun | 30 | 2020
Gliomas with mutations in what are called the isocitrate dehydrogenase (IDH) genes are the most common brain tumors diagnosed in younger adults aged 18 to 45 years. Patients can benefit from aggressive surgery, along with radiation and chemotherapy treatments, but these therapies are not curative in many cases.
Now a team led by investigators at Massachusetts General Hospital has uncovered a potentially promising strategy to target these tumors and improve treatment. The findings are published in Cancer Discovery, a journal of the American Association for Cancer Research.
Prior work by the group, led by Mass General’s Daniel Cahill, MD, PhD, Hiroaki Wakimoto, MD, PhD, and Julie Miller, MD, PhD, revealed that IDH mutant gliomas have a metabolic weakness making them especially susceptible to treatments that lower levels of NAD+, a ubiquitous and vital metabolic molecule, commonly thought of as the “currency of metabolism” in cells.
Also, previous work by other researchers found that chemotherapy activates an enzyme that stimulates NAD+ molecules to join together to make poly(ADP-ribose), or PAR, a key DNA damage signal. This PAR signal is a known susceptibility in IDH mutant gliomas. Researchers also discovered that activation of the enzyme by chemotherapy causes available NAD+ to be critically depleted for the production of PAR in IDH mutant glioma cells, but not normal cells.
These findings indicated that maintaining high PAR levels (and low NAD+ levels), in combination with chemotherapy, may uniquely target IDH mutant glioma cells. Considering this, Hiroaki Nagashima, MD, PhD, research fellow and lead author, devised a new treatment strategy and tested it in tumor cells and animal models.
“We found that maximum effectiveness was achieved by combining two agents: temozolomide, the chemotherapy most commonly used to treat patients with IDH mutant gliomas, with a drug that blocks PAR breakdown, known as a PAR glycohydrolase inhibitor,” said Dr. Cahill, a neurosurgical-oncologist at Mass General and an associate professor of neurosurgery at Harvard Medical School.
“We showed, for the first time, that PAR glycohydrolase inhibitors can be used to enhance the effectiveness of chemotherapy in tumors with metabolic weaknesses in the NAD+ pathway,” said Dr. Wakimoto, an associate professor of neurosurgery at Harvard Medical School.
Dr. Miller, an instructor in neurology and a neuro-oncologist at Mass General who treats patients with IDH mutant glioma, noted that PAR glycohydrolase inhibitors are a newly-emerging class of drugs. “The long-term significance is that, based on our findings, they could be tested in individuals with IDH mutant gliomas, with a goal of hopefully improving outcomes in these patients,” she said.
Paper cited: Hiroaki Nagashima H, Lee CK, Tateishi K, Higuchi F, Subramanian M, Rafferty S, Melamed L, Miller JJ, Wakimoto H and Cahill DP Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells. Cancer Discov June 30 2020 DOI: 10.1158/2159-8290.CD-20-0226
Funding: The research was supported by the National Cancer Institute of the National Institutes of Health, the Tawingo Fund, the Loglio Foundation, a Richard B. Simches Scholars Award, the Seeman Family Fund and the Overseas Research Fellowship of the Uehara Memorial Foundation.
About Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2019, Mass General was named #2 in the U.S. News & World Report list of "America’s Best Hospitals."
Our research integrates the full spectrum of "bench to bedside" discovery where lab scientists work alongside clinicians to improve patient care.
The study’s findings offer a potential alternative to surgical spaying
In a study of individuals at risk for developing type 2 diabetes, researchers identified genetic variants linked with participants’ responses to two different blood sugar–lowering drugs.
Research also offers new potential targeted interventions to mitigate the postoperative delirium-like behavior associated with Tauopathy in aged mice.
A Massachusetts General Hospital research team studies the impact of regulations on pregnant and postpartum individuals with opioid use disorder (OUD). Their findings were recently published in the Maternal and Child Health Journal.
DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR).
Understanding the link between the gut microbiome and polyp growth opens the door to potential screenings and treatments.